Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.39 |
| ▸ | CTSK | P43235 | 9/20 | 0.37 |
| ▸ | CTSS | P25774 | 5/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25537805 | 0.82 | CTSK (0.41) | ARCTSKCTSSKDM4EHSD17B10 | |
| SCHEMBL7219021 | 0.81 | AR (0.37) | ARCTSKCTSSKDM4EHSD17B10 | |
| SCHEMBL23832138 | 0.79 | PGK1 (0.44) | ARCTSKCTSSCYP11B2CYP19A1 | |
| SCHEMBL24517703 | 0.79 | CYP11B2 (0.41) | ARCYP11B1CYP11B2TRPV4 | |
| SCHEMBL7219799 | 0.77 | AR (0.40) | ARCTSKCTSSKDM4EHSD17B10 | |
| SCHEMBL19771880 | 0.77 | CTSK (0.40) | ARCTSKCTSSKDM4EHSD17B10 | |
| SCHEMBL23832146 | 0.77 | AR (0.43) | ARCTSKCTSSKDM4E | |
| SCHEMBL22778222 | 0.76 | USP8 (0.36) | CTSKCYP11B1CYP11B2 | |
| SCHEMBL29525213 | 0.76 | USP8 (0.36) | CTSKCYP11B1CYP11B2 | |
| SCHEMBL23832185 | 0.75 | TRPV4 (0.34) | ARCYP11B1CYP11B2TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4121423-B1 | TETRAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2026-04-29 | — | — | EP | disclosed |
| CN-115335371-B | Tetrazole derivatives | 默克专利股份公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240382468-A2 | TETRAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2024-11-21 | — | — | US | disclosed |
| US-20240009175-A9 | TETRAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2024-01-11 | — | — | US | disclosed |
| US-20230149371-A1 | TETRAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-05-18 | — | — | US | disclosed |
| US-20230149371-A1 | TETRAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-05-18 | — | — | US | disclosed |
| US-20230149371-A1 | TETRAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-05-18 | — | — | US | disclosed |
| EP-4121423-A1 | TETRAZOLE DERIVATIVES | Merck Patent GmbH (DE) | 2023-01-25 | — | — | EP | disclosed |
| CN-115335371-A | Tetrazole derivatives | 默克专利股份公司 | 2022-11-11 | — | — | CN | disclosed |
| WO-2021185793-A1 | TETRAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021185793-A1 | TETRAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009175-A9 | TETRAZOLE DERIVATIVES | VHL, BRCA1, POT1 | AR 4068/4885CTSK 1718/4885CTSS 3343/4885 |
| US-20240382468-A2 | TETRAZOLE DERIVATIVES | VHL, BRCA1, POT1 | AR 4068/4885CTSK 1718/4885CTSS 3343/4885 |
| US-20230149371-A1 | TETRAZOLE DERIVATIVES | VHL, BRCA1, POT1 | AR 4068/4885CTSK 1718/4885CTSS 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.